Stojanović Sanja, Ilić Marina Deijanin, Ilić Stevan, Petrović Dejan, Djukić Svetlana
Vojnosanit Pregl. 2015 Sep;72(9):779-84. doi: 10.2298/vsp140531067s.
BACKGROUND/AIM. Adiponectin exerts profound protective actions during insulin resistence or prediabetes progression towards more severe clinical entities such as metabolic syndrome and/or cardiovascular disease. Since hypoadiponectinaemia contributes to the pathophysiology of the metabolic syndrome and coronary artery disease the level of circulating adiponectin may be an early marker of cardiovascular events. The aim of this study was to determine the relationships between serum adiponectin levels and parameters of both insulin sensitivity and obesity in patients with the metabolic syndrome and/or coronary artery disease, as well as to assess predictive value of adiponectin serum levels as a biomarker of these entitetis.
The study included 100 patients with metabolic syndrome and/or coronary artery disease with different degree of insulin resistance and healthy, normoglycemic individuals. The control group comprising healthy, normoglycemic individuals was used for comparison. Serum level of adiponectin, fasting glucose, fasting insulinemia Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) index and anthropometric parameters were determined in all the subjects. Adiponectin was measured by using the ultrasensitive ELISA method. Insulinemia was measured by the radioimmunoassay (RIA) method. The presence of glycemic disorders was assessed on the basis of oral glucose tolerance test (OGTT). Results. Adiponectin level was inversely correlated with age (ρ = -0.015), parameters of both obesity (R = 0.437;p < 0.001) and insulin resistance (R = 0.374; p < 0.01). Decreasing in the level of adiponecrin was strongly implicated in the development of insulin resistance. Most importantly, a statistically significant rapid decrease ih adiponectin was in the prediabetic stages (p < 0.01). The predictor value of adiponectin was 1,356.32 ± 402.65 pg/mL.
The obtained resultats suggest that adiponectin may be a useful marker in identification of individuals with risk of developing metabolic syndrome and coronary artery disease, as well as a predictor of prediabetes.
背景/目的。脂联素在胰岛素抵抗或糖尿病前期向更严重的临床病症（如代谢综合征和/或心血管疾病）进展过程中发挥着重要的保护作用。由于低脂联素血症参与了代谢综合征和冠状动脉疾病的病理生理过程，循环脂联素水平可能是心血管事件的早期标志物。本研究的目的是确定代谢综合征和/或冠状动脉疾病患者血清脂联素水平与胰岛素敏感性及肥胖参数之间的关系，并评估脂联素血清水平作为这些病症生物标志物的预测价值。
本研究纳入了100例患有不同程度胰岛素抵抗的代谢综合征和/或冠状动脉疾病患者以及健康的血糖正常个体。以健康的血糖正常个体组成的对照组用于比较。测定了所有受试者的血清脂联素水平、空腹血糖、空腹胰岛素血症、胰岛素抵抗稳态模型评估（HOMA-IR）指数和人体测量参数。采用超敏ELISA法测定脂联素。采用放射免疫分析法（RIA）测定胰岛素血症。根据口服葡萄糖耐量试验（OGTT）评估血糖紊乱情况。结果。脂联素水平与年龄呈负相关（ρ = -0.015），与肥胖参数（R = 0.437；p < 0.001）和胰岛素抵抗参数（R = 0.374；p < 0.01）均呈负相关。脂联素水平降低与胰岛素抵抗的发生密切相关。最重要的是，在糖尿病前期阶段脂联素水平有统计学意义的快速下降（p < 0.01）。脂联素的预测值为1356.32 ± 402.65 pg/mL。
所得结果表明脂联素可能是识别有发生代谢综合征和冠状动脉疾病风险个体的有用标志物，也是糖尿病前期的预测指标。
